Lonza Expands Biopharmaceutical Partnership, Adding New Programs

By EC Assets · Published 1 July 2026

Lonza Group shares have risen following the expansion of its partnership with a leading U.S. biopharmaceutical company. The Swiss drug manufacturer added two biologics programs to the collaboration. This deepens a long-term agreement that includes new commercial biologics programs. The expanded partnership reinforces demand for Lonza's integrated contract development and manufacturing organization (CDMO) services. Lonza Group is a global leader in the life sciences ecosystem, alongside companies such as Kite, Thermo Fisher Scientific, and AstraZeneca. The firm is also considering building a $1 billion facility in Williamsburg Township. The global pharmaceutical sterility testing market is estimated to grow from $16.3 billion in 2026 to $35.3 billion by 2033. This growth represents a compound annual growth rate (CAGR) of 11.7%. The Stem Cell Biomanufacturing market is projected to reach $4015 million by 2034, up from $1730 million in 2025, at a CAGR of 13.1%. Contract development and manufacturing organizations (CDMOs) play a significant role in the biopharmaceutical sector. Companies like Lonza, Samsung Biologics, and WuXi Biologics highlight their CMC capabilities. The U.S. share of activity in this sector held at approximately 43%. Activity decreased to $3.9 billion from about $13 billion a year earlier, but continued to climb in the first half of 2026. This article is intended for informational purposes only. It does not constitute investment advice.